

# Xavier Filella Pla

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/96418/publications.pdf>

Version: 2024-02-01

179  
papers

9,086  
citations

26630

56  
h-index

46799

89  
g-index

185  
all docs

185  
docs citations

185  
times ranked

10828  
citing authors

#	ARTICLE	IF	CITATIONS
1	Value of PHI and PHID in the detection of intermediate- and high-risk prostate cancer. <i>Clinica Chimica Acta</i> , 2022, 531, 277-282.	1.1	8
2	Serum soluble CD23 levels are an independent predictor of time to first treatment in chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2022, 40, 588-595.	1.7	0
3	Impact of locking solutions on conditioning biofilm formation in tunnelled haemodialysis catheters and inflammatory response activation. <i>Journal of Vascular Access</i> , 2021, 22, 370-379.	0.9	6
4	A Rapid Amniotic Fluid Interleukin-6 Assessment for the Identification of Intra-Amniotic Inflammation in Women with Preterm Labor and Intact Membranes. <i>Fetal Diagnosis and Therapy</i> , 2021, 48, 327-332.	1.4	4
5	GuÃas de prÃctica clÃnica: oportunidad para visibilizar la importancia de la medicina del laboratorio. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2021, 2, 441-450.	0.2	0
6	An opportunity to emphasize the relevance of laboratory medicine. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2021, 2, 432-440.	0.2	0
7	Very high levels of PSA in patients with cardiogenic shock: Report of four clinical cases. <i>Clinical Biochemistry</i> , 2020, 76, 42-44.	1.9	2
8	Development and internal validation of a novel PHI-nomogram to identify aggressive prostate cancer. <i>Clinica Chimica Acta</i> , 2020, 501, 174-178.	1.1	11
9	Study of Biocompatibility of Membranes in Online Hemodiafiltration. <i>Blood Purification</i> , 2020, 49, 400-408.	1.8	6
10	Vertebral fracture risk in glucocorticoid-induced osteoporosis: the role of hypogonadism and corticosteroid boluses. <i>RMD Open</i> , 2020, 6, e001355.	3.8	5
11	High serum levels of IL-2R, IL-6, and TNF- $\alpha$ are associated with higher tumor burden and poorer outcome of follicular lymphoma patients in the rituximab era. <i>Leukemia Research</i> , 2020, 94, 106371.	0.8	7
12	Increased CSF levels of IL-1 $\beta$ , IL-6, and ACE in SARS-CoV-2-associated encephalitis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2020, 7, .	6.0	69
13	Hacia un cribado personalizado del cÃncer de prÃstata. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2020, 1, .	0.2	3
14	Towards personalized prostate cancer screening. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2020, 1, .	0.2	1
15	EvaluaciÃn del ensayo enanced estradiol (eE2) en el analizador Atellica IM 1600 de Siemens. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2020, 1, .	0.2	0
16	Performance evaluation of Siemens Atellica enhanced estradiol assay. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2020, 1, .	0.2	0
17	SP469STUDY OF BIOCOMPATIBILITY OF MEMBRANES IN HEMODIAFILTRACIÃN ON-LINE. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.7	0
18	Improved Control of Secondary Hyperparathyroidism in Hemodialysis Patients Switching from Oral Cinacalcet to Intravenous Etelcalcetide, Especially in Nonadherent Patients. <i>Blood Purification</i> , 2019, 48, 106-114.	1.8	10

#	ARTICLE	IF	CITATIONS
19	Serum CA 19.9 Levels in Patients With Benign and Malignant Disease: Correlation With the Serum Protein Electrophoretic Pattern. <i>Anticancer Research</i> , 2019, 39, 1079-1083.	1.1	6
20	Prostate cancer screening: guidelines review and laboratory issues. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1474-1487.	2.3	31
21	Tartrate-resistant acid phosphatase 5b, but not periostin, is useful for assessing Paget's disease of bone. <i>Bone</i> , 2019, 124, 132-136.	2.9	5
22	Neutrophil Gelatinase-Associated Lipocalin for Assessment of Acute Kidney Injury in Cirrhosis: A Prospective Study. <i>Hepatology</i> , 2019, 70, 319-333.	7.3	114
23	Identification of Potential miRNAs Biomarkers for High-Grade Prostate Cancer by Integrated Bioinformatics Analysis. <i>Pathology and Oncology Research</i> , 2019, 25, 1445-1456.	1.9	20
24	Significado cl�nico del aumento de los valores s�ricos de FGF-23 en la displasia fibrosa. <i>Medicina Cl�nica</i> , 2018, 151, 65-67.	0.6	2
25	Relationship Between CA 19.9 and the Lewis Phenotype: Options to Improve Diagnostic Efficiency. <i>Anticancer Research</i> , 2018, 38, 5883-5888.	1.1	35
26	Novel Biomarkers for Prostate Cancer Detection and Prognosis. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1095, 15-39.	1.6	19
27	FP576LOCKING SOLUTIONS IMPACT ON BIOFILM FORMATION IN TUNNELED HEMODIALYSIS CATHETERS AND ACTIVATION OF THE INFLAMMATORY RESPONSE. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i235-i235.	0.7	0
28	Clinical significance of increased serum levels of FGF-23 in fibrous dysplasia. <i>Medicina Cl�nica (English)</i> Tj ETQq0 0 0 rgBT /Overlock 10 T	0.2	1
29	Emerging biomarkers in the diagnosis of prostate cancer. <i>Pharmacogenomics and Personalized Medicine</i> , 2018, Volume 11, 83-94.	0.7	71
30	miRNAs as novel biomarkers in the management of prostate cancer. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 715-736.	2.3	89
31	Comparison of total, free and bioavailable 25-OH vitamin D determinations to evaluate its biological activity in healthy adults: the LabOscat study. <i>Osteoporosis International</i> , 2017, 28, 2457-2464.	3.1	19
32	High serum levels of soluble interleukin-2 receptor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) are associated with adverse clinical features and predict poor outcome in diffuse large B-cell lymphoma. <i>Leukemia Research</i> , 2017, 59, 20-25.	0.8	35
33	Exosomal and Non-Exosomal Urinary miRNAs in Prostate Cancer Detection and Prognosis. <i>Prostate</i> , 2017, 77, 573-583.	2.3	141
34	Concordance between direct and indirect measurements of free 25-OH vitamin D. <i>Clinica Chimica Acta</i> , 2017, 475, 169-171.	1.1	9
35	Analytical verification and method comparison of the ADVIA Centaur� Intact Parathyroid Hormone assay. <i>Clinical Biochemistry</i> , 2017, 50, 1222-1227.	1.9	6
36	Utility of proGRP as a tumor marker in the medullary thyroid carcinoma. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 441-446.	2.3	10

#	ARTICLE	IF	CITATIONS
37	The clinical value of biomarkers in respiratory complications in hematopoietic SCT. Bone Marrow Transplantation, 2017, 52, 415-422.	2.4	6
38	Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers. International Journal of Molecular Sciences, 2016, 17, 1784.	4.1	93
39	Automated measurement of 25-OH Vitamin D on the LUMIPULSE <sup>®</sup> G1200: analytical verification and method comparison. British Journal of Biomedical Science, 2016, 73, 104-109.	1.3	1
40	Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, e71-e77.	0.4	17
41	Assessment of a Combined Panel of Six Serum Tumor Markers for Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 427-437.	5.6	139
42	Reference intervals for bone turnover markers in Spanish premenopausal women. Clinical Chemistry and Laboratory Medicine, 2016, 54, 293-303.	2.3	26
43	Emerging biomarkers in the detection and prognosis of prostate cancer. Clinical Chemistry and Laboratory Medicine, 2015, 53, 963-73.	2.3	35
44	Identification of Candidates for Active Surveillance: Should We Change the Current Paradigm?. Clinical Genitourinary Cancer, 2015, 13, 499-504.	1.9	5
45	Prospective Study of Individualized or High Fixed Doses of Vitamin D Supplementation After Bariatric Surgery. Obesity Surgery, 2015, 25, 470-476.	2.1	25
46	Effect of Recent Spinal Cord Injury on Wnt Signaling Antagonists (Sclerostin and Dkk-1) and Their Relationship With Bone Loss. A 12-Month Prospective Study. Journal of Bone and Mineral Research, 2015, 30, 1014-1021.	2.8	29
47	The influence of prostate volume in prostate health index performance in patients with total PSA lower than 10 <sup>1</sup> / <sub>4</sub> g/L. Clinica Chimica Acta, 2014, 436, 303-307.	1.1	28
48	Clinical utility of %p2PSA and prostate health index in the detection of prostate cancer. Clinical Chemistry and Laboratory Medicine, 2014, 52, 1347-55.	2.3	43
49	Real-time PCR PCA3 assay is a useful test measured in urine to improve prostate cancer detection. Clinica Chimica Acta, 2014, 435, 53-58.	1.1	13
50	Variability of assay methods for total and free PSA after WHO standardization. Tumor Biology, 2014, 35, 1867-1873.	1.8	24
51	Differential humoral responses against heat-shock proteins after autologous stem cell transplantation in multiple myeloma. Annals of Hematology, 2014, 93, 107-111.	1.8	5
52	Risk Stratification for Advanced Colorectal Neoplasia According to Fecal Hemoglobin Concentration in a Colorectal Cancer Screening Program. Gastroenterology, 2014, 147, 628-636.e1.	1.3	94
53	Evaluation of [math>\phi^2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis. Clinical Chemistry and Laboratory Medicine, 2013, 51, 729-739.	2.3	129
54	Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem cell transplantation: long-term results from a single institution. Haematologica, 2013, 98, 1142-1146.	3.5	42

#	ARTICLE	IF	CITATIONS
55	Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover. <i>Bone</i> , 2013, 57, 272-276.	2.9	86
56	Nuclear factor- $\kappa$ B and interleukin-6 related docetaxel resistance in castration-resistant prostate cancer. <i>Prostate</i> , 2013, 73, 512-521.	2.3	52
57	PCA3 in the detection and management of early prostate cancer. <i>Tumor Biology</i> , 2013, 34, 1337-1347.	1.8	48
58	Prognostic Impact Of Serum Heavy/Light Chain Pairs In Patients With MGUS and Smoldering Myeloma: Long-Term Results From a Single Institution. <i>Blood</i> , 2013, 122, 3132-3132.	1.4	0
59	Circulating levels of HER-2/neu oncoprotein in breast cancer. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 5-21.	2.3	27
60	Efficacy of linezolid compared to vancomycin in an experimental model of pneumonia induced by methicillin-resistant <i>Staphylococcus aureus</i> in ventilated pigs*. <i>Critical Care Medicine</i> , 2012, 40, 162-168.	0.9	37
61	Prognostic Impact of Serum Immunoglobulin Heavy/Light Chain Ratio in Patients with Multiple Myeloma in Complete Remission after Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1076-1079.	2.0	29
62	CA 19-9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer. <i>Tumor Biology</i> , 2012, 33, 799-807.	1.8	42
63	Utility of serum tumor markers as an aid in the differential diagnosis of patients with clinical suspicion of cancer and in patients with cancer of unknown primary site. <i>Tumor Biology</i> , 2012, 33, 463-474.	1.8	52
64	Inflammatory impact of NOTES peritoneoscopy is not different from that of laparoscopy: a randomized comparative study in a survival porcine model. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2012, 26, 374-380.	2.4	10
65	Increased plasma concentrations of tumour markers in the absence of neoplasia. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 1605-20.	2.3	76
66	Emergence of oligoclonal bands in patients with multiple myeloma in complete remission after induction chemotherapy: association with the use of novel agents. <i>Haematologica</i> , 2011, 96, 171-173.	3.5	38
67	Clinical and inflammatory markers in amniotic fluid as predictors of adverse outcomes in preterm premature rupture of membranes. <i>American Journal of Obstetrics and Gynecology</i> , 2011, 205, 126.e1-126.e8.	1.3	60
68	Active surveillance in prostate cancer: the need to standardize. <i>Tumor Biology</i> , 2011, 32, 839-843.	1.8	9
69	HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. <i>Tumor Biology</i> , 2011, 32, 1087-1095.	1.8	133
70	Factors associated with inflammatory cytokine patterns in community-acquired pneumonia. <i>European Respiratory Journal</i> , 2011, 37, 393-399.	6.7	71
71	Comparison of Serum Human Epididymis Protein 4 with Cancer Antigen 125 as a Tumor Marker in Patients with Malignant and Nonmalignant Diseases. <i>Clinical Chemistry</i> , 2011, 57, 1534-1544.	3.2	167
72	Cytokine Systemic Pattern And Causal Microorganism In Community Acquired Pneumonia. , 2010, , .		0

#	ARTICLE	IF	CITATIONS
73	Response: Free light chain assay and stringent complete remission in multiple myeloma: more questions than answers. <i>Blood</i> , 2010, 115, 3414-3415.	1.4	0
74	Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance. <i>Blood</i> , 2010, 116, 4771-4776.	1.4	126
75	Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value. <i>Tumor Biology</i> , 2010, 31, 171-180.	1.8	61
76	Prospective Evaluation of Carcinoembryonic Antigen (CEA) and Carbohydrate Antigen 15.3 (CA 15.3) in Patients with Primary Locoregional Breast Cancer. <i>Clinical Chemistry</i> , 2010, 56, 1148-1157.	3.2	70
77	Stability in community-acquired pneumonia: one step forward with markers?. <i>Thorax</i> , 2009, 64, 987-992.	5.6	67
78	Predictive value of combined amniotic fluid proteomic biomarkers and interleukin-6 in preterm labor with intact membranes. <i>American Journal of Obstetrics and Gynecology</i> , 2009, 200, 499.e1-499.e6.	1.3	47
79	Re: Alberto Briganti, Michael L. Blute, James H. Eastham, et al. Pelvic Lymph Node Dissection in Prostate Cancer. <i>Eur Urol</i> 2009;55:1251-1255. <i>European Urology</i> , 2009, 56, e53.	1.9	2
80	Cervical length and gestational age at admission as predictors of intra-amniotic inflammation in preterm labor with intact membranes. <i>Ultrasound in Obstetrics and Gynecology</i> , 2009, 34, 441-447.	1.7	29
81	Usefulness of Serum Tumor Markers, Including Progastrin-Releasing Peptide, in Patients with Lung Cancer: Correlation with Histology. <i>Tumor Biology</i> , 2009, 30, 121-129.	1.8	94
82	Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. <i>Thorax</i> , 2009, 64, 587-591.	5.6	199
83	Abnormal serum free light chain ratio in patients with multiple myeloma in complete remission has strong association with the presence of oligoclonal bands: implications for stringent complete remission definition. <i>Blood</i> , 2009, 114, 4954-4956.	1.4	60
84	Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents. <i>Cytokine</i> , 2008, 41, 244-253.	3.2	41
85	Markers of treatment failure in hospitalised community acquired pneumonia. <i>Thorax</i> , 2008, 63, 447-452.	5.6	156
86	Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel. <i>Annals of Oncology</i> , 2008, 19, 269-275.	1.2	19
87	Impact of Ultrasensitive Cardiac Troponin I Dynamic Changes in the New Universal Definition of Myocardial Infarction. <i>American Journal of Clinical Pathology</i> , 2008, 130, 964-968.	0.7	23
88	Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as Tumor Markers in Patients with Lung Cancer: Comparison with CYFRA 21-1, CEA, SCC and NSE. <i>Tumor Biology</i> , 2008, 29, 371-380.	1.8	107
89	Cytokine-Release Patterns in Elderly Patients with Systemic Inflammatory Response Syndrome. <i>Gerontology</i> , 2007, 53, 239-244.	2.8	23
90	Th1/Th2 Cytokine Release Pattern During In Vivo Cytomegalovirus Disease in Solid Organ Transplantation. <i>Transplantation Proceedings</i> , 2007, 39, 2233-2235.	0.6	17

#	ARTICLE	IF	CITATIONS
91	Monoclonal Gammopathy of Undetermined Significance: Predictors of Malignant Transformation and Recognition of an Evolving Type Characterized by a Progressive Increase in M Protein Size. <i>Mayo Clinic Proceedings</i> , 2007, 82, 428-434.	3.0	76
92	Evaluation of a new ultrasensitive assay for cardiac troponin I. <i>Clinical Biochemistry</i> , 2007, 40, 1406-1413.	1.9	45
93	117: Intra-amniotic inflammation in preterm labor with intact membranes as a marker of adverse perinatal outcomes. <i>American Journal of Obstetrics and Gynecology</i> , 2007, 197, S46.	1.3	0
94	Usefulness of proprostate-specific antigen in the diagnosis of prostate cancer. <i>Anticancer Research</i> , 2007, 27, 607-10.	1.1	6
95	Prospective evaluation of procalcitonin in adults with non-neutropenic fever after allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2006, 37, 499-502.	2.4	24
96	Vascular endothelial growth factor serum concentrations in hypercholesterolemic patients. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2006, 66, 261-267.	1.2	26
97	Interleukin 6, a Nuclear Factor- $\kappa$ B Target, Predicts Resistance to Docetaxel in Hormone-Independent Prostate Cancer and Nuclear Factor- $\kappa$ B Inhibition by PS-1145 Enhances Docetaxel Antitumor Activity. <i>Clinical Cancer Research</i> , 2006, 12, 5578-5586.	7.0	147
98	Low utility of CYFRA 21-1 serum levels for diagnosis and follow-up in bladder cancer patients. <i>Journal of Clinical Laboratory Analysis</i> , 2005, 19, 167-171.	2.1	8
99	Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer. <i>Anticancer Research</i> , 2005, 25, 1773-8.	1.1	66
100	Pro-Gastrin-Releasing Peptide in Patients with Benign and Malignant Diseases. <i>Tumor Biology</i> , 2004, 25, 56-61.	1.8	44
101	Evaluation of Inflammatory and Renal-Injury Markers in Women Treated with Antibiotics for Acute Pyelonephritis Caused by <i>Escherichia coli</i> . <i>Vaccine Journal</i> , 2004, 11, 142-146.	2.6	18
102	Inflammatory response associated with pulmonary complications in non-HIV immunocompromised patients. <i>Thorax</i> , 2004, 59, 1081-1088.	5.6	18
103	Inflammatory Responses in Blood Samples of Human Immunodeficiency Virus-Infected Patients with Pulmonary Infections. <i>Vaccine Journal</i> , 2004, 11, 608-614.	3.1	20
104	Prospective evaluation of procalcitonin in adults with febrile neutropenia after haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2004, 126, 372-376.	2.5	31
105	Effect of hemodialysis and renal failure on serum biochemical markers of bone turnover. <i>Journal of Bone and Mineral Metabolism</i> , 2004, 22, 254-259.	2.7	32
106	ProGRP: a new biomarker for small cell lung cancer. <i>Clinical Biochemistry</i> , 2004, 37, 505-511.	1.9	118
107	Response to thalidomide in multiple myeloma: impact of angiogenic factors. <i>Cytokine</i> , 2004, 26, 145-148.	3.2	34
108	Comparison of several combinations of free, complexed, and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms. <i>Urology</i> , 2004, 63, 1100-1103.	1.0	9

#	ARTICLE	IF	CITATIONS
109	Causes and predictors of nonresponse to treatment of intensive care unit-acquired pneumonia*. Critical Care Medicine, 2004, 32, 938-945.	0.9	132
110	Antígeno prostático específico y sus fracciones en el diagnóstico del cáncer de próstata. Medicina Clínica, 2004, 122, 241-244.	0.6	2
111	Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica, 2004, 89, 832-6.	3.5	100
112	Complexed prostate-specific antigen for the detection of prostate cancer. Anticancer Research, 2004, 24, 4181-5.	1.1	2
113	Serum osteoprotegerin and its ligand in Paget's disease of bone: Relationship to disease activity and effect of treatment with bisphosphonates. Arthritis and Rheumatism, 2003, 48, 824-828.	6.7	57
114	Smoldering multiple myeloma: natural history and recognition of an evolving type. British Journal of Haematology, 2003, 123, 631-636.	2.5	119
115	Relationship of p53 with other Oncogenes, Cytokines and Systemic Lupus Erythematosus Activity. Tumor Biology, 2003, 24, 185-188.	1.8	25
116	Usefulness of tissue polypeptide antigen in the follow-up of bladder cancer. Urology, 2003, 62, 243-248.	1.0	5
117	Effect of proinflammatory cytokines (IL-6, TNF- $\alpha$ , IL-1 $\beta$ ) on hemodynamic performance during orthotopic liver transplantation. Transplantation Proceedings, 2003, 35, 1884-1887.	0.6	42
118	Association between anatomopathologic graft disorders during reperfusion and vena cava sIL-2r in orthotopic liver transplantation. Transplantation Proceedings, 2003, 35, 1880-1883.	0.6	1
119	Increased tumour necrosis factor- $\alpha$ plasma levels during moderate-intensity exercise in COPD patients. European Respiratory Journal, 2003, 21, 789-794.	6.7	143
120	Tumor Markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in Patients with Non-Small Cell Lung Cancer as an Aid in Histological Diagnosis and Prognosis. Tumor Biology, 2003, 24, 209-218.	1.8	233
121	Pulmonary Infiltrates in Patients Receiving Long-term Glucocorticoid Treatment*. Chest, 2003, 123, 488-498.	0.8	80
122	Prospective Evaluation of Squamous Cell Carcinoma and Carcinoembryonic Antigen as Prognostic Factors in Patients with Cervical Cancer. Tumor Biology, 2003, 24, 156-164.	1.8	36
123	Valor de las citocinas proinflamatorias como factor de predicción de sepsis y mortalidad en el anciano con fiebre. Medicina Clínica, 2003, 121, 361-366.	0.6	3
124	Clinical evaluation of the Elecsys CA 15-3 test in breast cancer patients. Clinical Laboratory, 2003, 49, 15-24.	0.5	22
125	Elevation of serum levels of the anti-inflammatory cytokine interleukin-10 and decreased risk of coronary events in patients with unstable angina. American Heart Journal, 2002, 144, 811-817.	2.7	112
126	S-100 Protein Serum Levels in Patients with Benign and Malignant Diseases: False-Positive Results Related to Liver and Renal Function. Tumor Biology, 2002, 23, 39-44.	1.8	56



#	ARTICLE	IF	CITATIONS
127	Th1/Th2 cytokine imbalance in patients with Sjögren syndrome secondary to hepatitis C virus infection. <i>Seminars in Arthritis and Rheumatism</i> , 2002, 32, 56-63.	3.4	36
128	A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. <i>Arthritis and Rheumatism</i> , 2002, 47, 29-35.	6.7	127
129	Interleukin 6 and tumour necrosis factor alpha serum levels in monoclonal gammopathy of undetermined significance. <i>British Journal of Haematology</i> , 2002, 117, 387-389.	2.5	7
130	UNDETECTABLE PROSTATE SPECIFIC ANTIGEN IN DISSEMINATED PROSTATE CANCER. <i>Journal of Urology</i> , 2001, 166, 993-993.	0.4	7
131	Evaluation of the Analytical and Clinical Performance of the Elecsys® CA 15-3 Immunoassay. <i>Clinical Chemistry</i> , 2001, 47, 2162-2164.	3.2	13
132	Systemic inflammatory response after bronchoalveolar lavage in critically ill patients. <i>European Respiratory Journal</i> , 2001, 17, 274-280.	6.7	10
133	Influence of AFP, CEA and PSA on the in vitro Production of Cytokines. <i>Tumor Biology</i> , 2001, 22, 67-71.	1.8	6
134	Acute phase response in laparoscopic and open colectomy in colon cancer. <i>Diseases of the Colon and Rectum</i> , 2001, 44, 638-646.	1.3	163
135	Bronchial Inflammation and Colonization in Patients with Clinically Stable Bronchiectasis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001, 164, 1628-1632.	5.6	223
136	Measurement of complexed PSA in the differential diagnosis between prostate cancer and benign prostate hyperplasia. , 2000, 42, 181-185.		31
137	Analysis of type T1 and T2 cytokines in patients with prostate cancer. <i>Prostate</i> , 2000, 44, 271-274.	2.3	54
138	Evaluation of CD30 as a marker for Th2 lymphocytes in bronchoalveolar lavage in interstitial lung diseases. <i>Respiratory Medicine</i> , 2000, 94, 345-349.	2.9	8
139	Prognostic value of serum cytokines in patients with congestive heart failure. <i>Journal of Heart and Lung Transplantation</i> , 2000, 19, 419-425.	0.6	109
140	Evaluation of a Multivariate Prostate-Specific Antigen and Percentage of Free Prostate-Specific Antigen Logistic Regression Model in the Diagnosis of Prostate Cancer. <i>Tumor Biology</i> , 1999, 20, 312-318.	1.8	3
141	Endothelial Cell Activation in Muscle Biopsy Samples Is Related to Clinical Severity in Human Cerebral Malaria. <i>Journal of Infectious Diseases</i> , 1999, 179, 475-483.	4.0	23
142	Peritoneal response to a septic challenge. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 1999, 13, 792-796.	2.4	56
143	Calcitriol-Mediated Hypercalcaemia and Increased Interleukins in a Patient with Sarcoid Myopathy. <i>Clinical Rheumatology</i> , 1999, 18, 488-491.	2.2	1
144	Cytokine-induced inflammation and long-term stroke functional outcome. <i>Journal of the Neurological Sciences</i> , 1999, 162, 185-188.	0.6	72

#	ARTICLE	IF	CITATIONS
145	Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study. <i>European Respiratory Journal</i> , 1999, 14, 218.	6.7	153
146	Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. <i>European Respiratory Journal</i> , 1999, 14, 1015-1022.	6.7	318
147	Cytokine expression in severe pneumonia: A bronchoalveolar lavage study. <i>Critical Care Medicine</i> , 1999, 27, 1745-1753.	0.9	164
148	c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value. <i>Breast Cancer Research and Treatment</i> , 1998, 51, 109-119.	2.5	104
149	Serum levels of Î²2-microglobulin, neopterin, TNF-Î± and soluble receptors of TNF-Î± and interleukin-2 in intravenous drug abusers according to HIV-1 status and stage of the HIV-1 infection. <i>Clinical Microbiology and Infection</i> , 1998, 4, 4-10.	6.0	10
150	Serum interleukin-6 in congestive heart failure secondary to idiopathic dilated cardiomyopathy. <i>American Journal of Cardiology</i> , 1998, 82, 688-690.	1.6	82
151	Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: Relationship with the development of renal impairment and mortality. <i>Hepatology</i> , 1998, 27, 1227-1232.	7.3	387
152	Value of postoperative surveillance after radical surgery for colorectal cancer. <i>Diseases of the Colon and Rectum</i> , 1998, 41, 714-723.	1.3	99
153	Interleukin-4, interleukin-10, and granulocyte-macrophage colony stimulating factor in second-trimester serum from women with preeclampsia. <i>Obstetrics and Gynecology</i> , 1998, 92, 849-853.	2.4	22
154	IMPAIRED PRODUCTION OF INTERLEUKIN 6 AND TUMOUR NECROSIS FACTOR Î± IN WHOLE BLOOD CELL CULTURES OF PATIENTS WITH MULTIPLE MYELOMA. <i>Cytokine</i> , 1998, 10, 993-996.	3.2	9
155	Randomized trial of adjuvant chemotherapy with mitomycin plus fluorouracil versus mitomycin alone in resected locally advanced gastric cancer. <i>Journal of Clinical Oncology</i> , 1998, 16, 1036-1039.	1.6	53
156	CA 125 in Biological Fluids. <i>International Journal of Biological Markers</i> , 1998, 13, 224-230.	1.8	31
157	Free and Total PSA in the Diagnosis of Prostate Cancer. <i>Tumor Biology</i> , 1997, 18, 332-340.	1.8	12
158	Serum Levels of C-erbB-2 (HER-2/neu) in Patients with Malignant and Non-Malignant Diseases. <i>Tumor Biology</i> , 1997, 18, 188-196.	1.8	63
159	Clinical evaluation of free PSA/Total PSA (Prostate-specific Antigen) ratio in the diagnosis of prostate cancer. <i>European Journal of Cancer</i> , 1997, 33, 1226-1229.	2.8	16
160	Value of PSA (prostate-specific antigen) in the detection of prostate cancer in patients with urological symptoms. Results of a multicentre study. <i>European Journal of Cancer</i> , 1996, 32, 1125-1128.	2.8	15
161	Multicentre Clinical Evaluation of the COBAS CORE CEA, CA 125 II and PSA Tumor Marker Assays. <i>International Journal of Biological Markers</i> , 1996, 11, 40-45.	1.8	3
162	Prognostic Significance of SCC Antigen in the Serum of Patients with Head and Neck Cancer. <i>Tumor Biology</i> , 1996, 17, 81-89.	1.8	32

#	ARTICLE	IF	CITATIONS
163	Usefulness of Prostate-Specific Antigen Density as a Diagnostic Test of Prostate Cancer. <i>Tumor Biology</i> , 1996, 17, 20-26.	1.8	10
164	Acute Phase is the Only Significantly Reduced Component of the Injury Response after Laparoscopic Cholecystectomy. <i>World Journal of Surgery</i> , 1996, 20, 528-534.	1.6	49
165	Prostate-specific antigen detection by ultrasensitive assay in samples from women. , 1996, 29, 311-316.		16
166	Detection of nonprostatic PSA in serum and nonserum samples from women. , 1996, 68, 424-427.		22
167	Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3. <i>British Journal of Cancer</i> , 1996, 74, 1126-1131.	6.4	64
168	Clinical usefulness of free PSA fraction as an indicator of prostate cancer. <i>International Journal of Cancer</i> , 1995, 63, 780-784.	5.1	35
169	Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 1995, 36, 41-48.	2.5	108
170	Carcinoembryonic Antigen in Staging and Follow-Up of Patients with Solid Tumors. <i>Tumor Biology</i> , 1995, 16, 32-41.	1.8	97
171	Cyfra 21â€™1 in Lung Cancer: Comparison with Cea, Ca 125, Scc and Nse Serum Levels. <i>International Journal of Biological Markers</i> , 1994, 9, 96-101.	1.8	42
172	Study of a New Tumor Marker, CYFRA21-1, in Malignant and Nonmalignant Diseases. <i>Tumor Biology</i> , 1994, 15, 318-325.	1.8	59
173	REDUCED ACTIVITY OF SERUM CREATINE KINASE IN RHEUMATOID ARTHRITIS: A PHENOMENON LINKED TO THE INFLAMMATORY RESPONSE. <i>Rheumatology</i> , 1994, 33, 231-234.	1.9	24
174	Tag-72, CA 19.9 and CEA as Tumor Markers in Gastric Cancer. <i>Acta OncolÃ³gica</i> , 1994, 33, 747-751.	1.8	20
175	SERUM CYTOKINES (IL-6, TNF-Î±, IL-1Î² AND IFN-Î³) IN ANKYLOSING SPONDYLITIS: A CLOSE CORRELATION BETWEEN SERUM IL-6 AND DISEASE ACTIVITY AND SEVERITY. <i>Rheumatology</i> , 1994, 33, 927-931.	1.9	299
176	Use of CA 19-9 in the Early Detection of Recurrences in Colorectal Cancer: Comparison with CEA. <i>Tumor Biology</i> , 1994, 15, 1-6.	1.8	34
177	A Prospective Study of Tumor Markers CA 125 and CA 19.9 in Patients with Epithelial Ovarian Carcinomas. <i>Tumor Biology</i> , 1992, 13, 278-286.	1.8	31
178	Prognostic Value of CA 19.9 Levels in Colorectal Cancer. <i>Annals of Surgery</i> , 1992, 216, 55-59.	4.2	101
179	Tumor Markers in Chronic Renal Failure and Hemodialysis Patients. <i>Nephron</i> , 1991, 57, 183-186.	1.8	66